Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
225Ac-LNC1011 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
7 August 2026
225Ac-LNC1011: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
4SCAR-PSMA(Shenzhen Geno-Immune Medical Institute) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
7 August 2026
4SCAR-PSMA(Shenzhen Geno-Immune Medical Institute): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals.
8 min read
Autologou tumor mRNA transfected dendritic cells (Oslo University Hospital) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
7 August 2026
Autologou tumor mRNA transfected dendritic cells (Oslo University Hospital): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers.
8 min read
EcoActive(Intralytix) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
7 August 2026
EcoActive(Intralytix): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
VP-001 (PYC Therapeutics) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
7 August 2026
VP-001 (PYC Therapeutics): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Miromatrix, Inc Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
7 August 2026
Miromatrix, Inc BD opportunity scan covering pipeline ownership, stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale using PatSnap MCP.
Latest Hotspot
8 min read
Cantero Therapeutics, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
7 August 2026
Cantero Therapeutics, Inc. BD opportunity scan covering pipeline ownership, stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale using PatSnap MCP.
8 min read
Fecal Microbial Transplantation(Ella Therapeutics) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
7 August 2026
Fecal Microbial Transplantation(Ella Therapeutics): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals.
Latest Hotspot
8 min read
Fortify Therapeutics, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
7 August 2026
Fortify Therapeutics, Inc. BD opportunity scan covering pipeline ownership, stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale using PatSnap MCP.
8 min read
ACP-211 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
7 August 2026
ACP-211: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Aspa Therapeutics, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
7 August 2026
Aspa Therapeutics, Inc. BD opportunity scan covering pipeline ownership, stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale using PatSnap MCP.
8 min read
NMI-900 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
7 August 2026
NMI-900: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.